Pfizer sends Covid vaccine to FDA for approval, to disperse in December

• In addition to today’s submission to the FDA, the business have actually already initiated rolling submissions across the globe including in Australia, Canada, Europe, Japan and the U.K., and plan to send applications immediately to other regulatory agencies around the globe
• Based upon present projections, the companies expect to produce internationally up to 50 million doses in 2020 and up to 1.3 billion doses by the end of 2021; the business will be prepared to distribute the vaccine within hours after authorization
• BNT162 b2 demonstrated a vaccine effectiveness rate of 95%, without any severe security concerns observed to date

NEW YORK & MAINZ, Germany–( BUSINESS WIRE)–.
Pfizer Inc.(NYSE: PFE) and BioNTech SE(Nasdaq: BNTX) revealed they will send a demand today to the U.S. Food and Drug Administration (FDA) for Emergency Usage Permission (EUA) of their mRNA vaccine candidate, BNT162 b2 versus SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December2020

This press release includes multimedia. View the complete release here: https://www.businesswire.com/news/home/20201120005370/ en/

The submission is based upon a vaccine effectiveness rate of 95%(p< 0.0001) showed in the business' Phase 3 clinical research study in individuals without previous SARS-CoV-2 infection (first main objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case determined from 7 days after the 2nd dose. The very first primary unbiased analysis was based on 170 confirmed cases of COVID-19 This submission also is supported by obtained safety information from a randomized subset of approximately 8,000 individuals ≥18 years of age and unsolicited security data from roughly 38,000 trial individuals who have actually been followed for a typical of 2 months following the 2nd dose of the vaccine candidate. The submission also consists of solicited safety information on around 100 children 12-15 years of age. Roughly 42%of global participants and 30%of U.S. individuals in the Phase 3 study have racially and ethnically varied backgrounds, and 41%of worldwide and 45%of U.S. participants are 56-85 years of age. To date, the Data Monitoring Committee (DMC) for the study has actually not reported any severe security issues related to the vaccine.

” Our work to deliver a safe and reliable vaccine has never ever been more immediate, as we continue to see a worrying increase in the variety of cases of COVID-19 internationally. Filing in the U.S. represents a vital milestone in our journey to provide a COVID-19 vaccine to the world and we now have a more total picture of both the efficacy and safety profile of our vaccine, offering us confidence in its capacity,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We anticipate the upcoming Vaccines and Related Biological Products Advisory Committee conversation and continue to work carefully with the FDA and regulatory authorities worldwide to secure authorization of our vaccine prospect as rapidly as possible.”.

” Declare Emergency Situation Usage Authorization in the U.S. is a crucial action in making our vaccine prospect available to the global population as quickly as possible,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “We plan to continue to work with regulatory firms worldwide to enable the fast circulation of our vaccine worldwide. As a company located in Germany in the heart of Europe, our interactions with the European Medicines Company (EMA) are of particular value to us and we have continually supplied data to them as part of our rolling review procedure.”.

The companies have currently started rolling submissions with numerous regulative agencies around the world, including the EMA and the Medicines & Healthcare Products Regulatory Firm (MHRA) in the UK, and plan to submit applications to other regulatory companies worldwide in the coming days. In some cases, governments might have regulative pathways comparable to an EUA. The business will be all set to distribute the vaccine prospect within hours after permission.

Pfizer and BioNTech are extremely grateful to the research study volunteers and investigative website personnel in the medical trial program, as their participation was crucial to today’s important milestone in the business’ efforts to attend to the COVID-19 global pandemic.

The BNT162 b2 vaccine candidate is not currently authorized for circulation throughout the world. Both collaborators are committed to establishing this novel vaccine with preclinical and clinical data at the leading edge of all their decision making.

Manufacturing and Delivery Abilities

While Pfizer and BioNTech await potential permission or approval from regulative firms, the companies continue to work in cooperation with governments and Ministries of Health all over the world that will distribute the vaccine, subject to authorization or approval, to help ensure it can reach those most in need as quickly as possible.

Pfizer is bringing its leading in-house production abilities to this effort, with the ability and experience to rapidly scale, produce and disperse big amounts of vaccine at high quality, leveraging multiple sites in the U.S. and Europe, and matching the mRNA manufacturing expertise of BioNTech, acquired over practically a decade. Pfizer and BioNTech’s combined production network has the possible to supply up to 50 million vaccine doses worldwide in 2020 and as much as 1.3 billion dosages by the end of 2021 (based on clinical success, making capability, and regulative approval or authorization).

Pfizer has vast experience and competence in cold-chain shipping and has a recognized facilities to supply the vaccine worldwide, consisting of circulation hubs that can store vaccine dosages for up to six months. As soon as thawed, the vaccine vial can be kept for up to 5 days at cooled (2 – 8 ^o C) conditions.

From the start of the research study program earlier this year, Pfizer and BioNTech have actually successfully provided and distributed their investigational vaccine to more than 150 medical trial sites throughout the U.S., along with Europe, Latin America, and South Africa. Based on their collective experience, the companies think in their capability to distribute the vaccine worldwide upon approval or permission.

About the Study

The Stage 3 scientific trial of BNT162 b2, which is based upon BioNTech’s proprietary mRNA innovation, began on July 27 and has registered 43,661 individuals to date, 41,135 of whom have gotten a second dose of the vaccine candidate as of November 13,2020 A breakdown of the variety of medical trial participants can be found here from around 150 scientific trials websites in the U.S., Germany, Turkey, South Africa, Brazil and Argentina. Participants will continue to be kept an eye on for long-term protection and safety for an additional 2 years after their 2nd dosage.

Pfizer and BioNTech plan to submit the efficacy and safety data from the research study for peer-review in a scientific journal when analysis of the information is finished.

About Pfizer: Breakthroughs That Modification Clients’ Lives

We strive to set the requirement for quality, safety and worth in the discovery, development and manufacture of health care products, consisting of ingenious medicines and vaccines. Every day, Pfizer colleagues work across established and emerging markets to advance health, prevention, treatments and cures that challenge the most feared illness of our time. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/ Pfizer

Pfizer Disclosure Notification

The info consisted of in this release is as of November 20,2020 Pfizer assumes no obligation to update positive statements consisted of in this release as the outcome of brand-new details or future occasions or developments.

This release consists of positive information about Pfizer’s efforts to combat COVID-19, the collaboration in between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program and modRNA prospect BNT162 b2 (consisting of qualitative evaluations of offered information, prospective benefits, expectations for medical trials, the submission of a request for Emergency Use Authorization and other regulative submissions, the expected timing of regulatory submissions, regulative approval or authorization and prepared for manufacturing, circulation and supply), that involves considerable risks and unpredictabilities that could trigger real outcomes to differ materially from those expressed or suggested by such statements. Dangers and unpredictabilities consist of, to name a few things, the unpredictabilities inherent in research study and advancement, including the ability to fulfill expected medical endpoints, start and/or conclusion dates for clinical trials, regulatory submission dates, regulative approval dates and/or launch dates, as well as threats related to clinical information (including the Phase 3 data), including the possibility of unfavorable brand-new preclinical or scientific trial information and additional analyses of existing preclinical or medical trial information; the ability to produce comparable scientific or other outcomes, consisting of the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Stage 3 trial or in larger, more varied populations upon commercialization; the danger that medical trial data go through varying analyses and evaluations, including throughout the peer review/publication process, in the clinical community normally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be released in clinical journal publications and, if so, when and with what adjustments; whether regulatory authorities will be pleased with the style of and results from these and any future preclinical and scientific research studies; whether and when any other biologics license and/or emergency utilize authorization applications might be submitted in any jurisdictions for BNT162 b2 or any other possible vaccine prospects; whether and when any such applications might be authorized by regulative authorities, which will depend upon myriad elements, consisting of making a decision as to whether the vaccine prospect’s benefits surpass its known threats and decision of the vaccine candidate’s effectiveness and, if authorized, whether it will be commercially effective; decisions by regulative authorities impacting labeling, manufacturing procedures, safety and/or other matters that might affect the availability or commercial capacity of a vaccine, consisting of advancement of items or treatments by other business; disruptions in the relationships between us and our partnership partners or third-party suppliers; risks connected to the availability of raw materials to manufacture a vaccine; obstacles related to our vaccine candidate’s ultra-low temperature level solution and attendant storage, distribution and administration requirements, including threats associated with dealing with after shipment by Pfizer; the threat that we may not have the ability to successfully establish non-frozen formulations; the danger that we might not have the ability to produce or scale up making capacity on a prompt basis or have access to logistics or supply channels commensurate with international need for any possible approved vaccine, which would negatively affect our capability to supply the approximated varieties of doses of our vaccine candidate within the projected time periods suggested; whether and when additional supply agreements will be reached; uncertainties concerning the ability to acquire suggestions from vaccine technical committees and other public health authorities and unpredictabilities regarding the commercial impact of any such suggestions; uncertainties concerning the effect of COVID-19 on Pfizer’s business, operations and monetary results; and competitive developments.

A more description of dangers and unpredictabilities can be found in Pfizer’s Yearly Report on Form 10- K for the fiscal year ended December 31, 2019 and in its subsequent reports on Kind 10- Q, including in the sections thereof captioned “Danger Aspects” and “Forward-Looking Info and Factors That May Affect Future Results”, in addition to in its subsequent reports on Type 8-K, all of which are submitted with the U.S. Securities and Exchange Commission and readily available at www.sec.gov and www.pfizer.com

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel treatments for cancer and other major diseases. The Company makes use of a large variety of computational discovery and restorative drug platforms for the fast advancement of novel biopharmaceuticals. Its broad portfolio of oncology product prospects includes personalized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small particles. Based on its deep knowledge in mRNA vaccine development and in-house production capabilities, BioNTech and its partners are establishing several mRNA vaccine prospects for a series of infectious diseases alongside its varied oncology pipeline. BioNTech has actually developed a broad set of relationships with numerous worldwide pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more details, please see www.BioNTech.de

BioNTech Forward-looking statements

These positive declarations may include, however might not be restricted to, statements worrying: BioNTech’s efforts to fight COVID-19; the cooperation between BioNTech and Pfizer to develop a prospective COVID-19 vaccine; our expectations concerning the potential qualities of BNT162 b2 in our Stage 2/3 trial and/or in industrial usage based on information observations to date; the expected timepoint for extra readouts on effectiveness data of BNT162 b2 in our Phase 2/3 trial; the nature of the scientific information, which is subject to continuous peer review, regulatory review and market analysis; the timing for submission of information for, or receipt of, any marketing approval or Emergency situation Use Permission; the timing for submission of manufacturing information to the FDA; our contemplated shipping and storage plan, including our estimated item shelflife at different temperatures; and the capability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market need, including our production estimates for 2020 and2021 These dangers and uncertainties include, however are not limited to: the ability to meet the pre-defined endpoints in scientific trials; competition to produce a vaccine for COVID-19; the ability to produce equivalent medical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in bigger, more varied populations upon commercialization; the ability to successfully scale our productions capabilities; and other possible troubles. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Existing Report on Type 6-K submitted with the SEC on November 10, which is readily available on the SEC’s site at www.sec.gov

View source version on businesswire.com: https://www.businesswire.com/news/home/20201120005370/ en/

Pfizer:

Media Relations.


Amy Rose.


1 (212) 733-7410


[email protected]

Financier Relations.


Chuck Triano.


1 (212) 733-3901


[email protected]

BioNTech:

Media Relations.


Jasmina Alatovic.


49 (0 )61319084 1513 or 49(0 )15119781385


[email protected]

Financier Relations.


Sylke Maas, Ph.D.


49 (0 )613190841074


[email protected]

Source: Pfizer Inc.

Learn More

http://cnacertificationprogram.net/pfizer-sends-covid-vaccine-to-fda-for-approval-to-disperse-in-december/